Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2026-07-20), Hansa Biopharma AB's 50-Day SMA is kr32.78. It's 20-Day SMA is kr34.11 and 200-Day SMA is kr32.10.
Hansa Biopharma AB (LTS:0RC7) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
Hansa Biopharma AB 50-Day SMA Related Terms
LTS:0RC7 vs VRTX, REGN, ALNY: 50-Day SMA Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB 50-Day SMA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's 50-Day SMA falls into.
Hansa Biopharma AB (LTS:0RC7) 50-Day SMA Calculation
The formula for calculating SMA is:
SMA
=
( P1 + P2 + ... + Pn )
/
n
where:
Pn is the price of the stock at period n.
n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (LTS:0RC7) has a 50-Day SMA of kr32.78 as of Jul. 20, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's 50-Day SMA too high?
Hansa Biopharma AB's current 50-Day SMA is kr32.78. Overall, Hansa Biopharma AB has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's 50-Day SMA compare to VRTX and REGN?
Hansa Biopharma AB's 50-Day SMA of kr32.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current 50-Day SMA is kr32.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (LTS:0RC7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.49, compared to a current price of kr32.02 — trading 30.7% above its estimated fair value. The current 50-Day SMA is kr32.78. Hansa Biopharma AB's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Hansa Biopharma AB (LTS:0RC7), the current 50-Day SMA is kr32.78 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (LTS:0RC7) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr32.02 is trading 30.7% above its estimated GF Value™ of kr24.49.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for LTS:0RC7:
50-Day SMA: kr32.78
GF Value™: kr24.49 vs. price of kr32.02 (30.7% above fair value)
No single metric tells the full story. See the LTS:0RC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
61GF Score
Get the complete analysis for LTS:0RC7
50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RC7 has been successfully added to your 
